Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dom.12467 http://scihub22266oqcxt.onion/10.1111/dom.12467 C4676912!4676912 !25787200     free     free     free       Diabetes+Obes+Metab 2015 ; 17 (7 ): 675-81 Nephropedia Template TP {{tp|p=25787200 |t=2015. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial |pdf=|usr=}}{{25787200 }} gab.com Text Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial JO: Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=25787200 #FOAvip AIM: To assess the efficacy and safety of fasiglifam 25 and 50?mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. METHODS: This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasiglifam 25?mg (n?=?63) or 50?mg (n?=?62) or placebo (n?=?67) for 24?weeks. The primary efficacy endpoint was the change from baseline in glycated haemoglobin (HbA1c) at week 24. RESULTS: At week 24, both fasiglifam groups had significantly reduced HbA1c levels compared with the placebo group (p?<?0.0001). The least squares mean change from baseline in HbA1c was 0.16% with placebo, -0.57% with fasiglifam 25?mg and -0.83% with fasiglifam 50?mg. The percentage of patients who achieved an HbA1c target of <6.9% at week 24 was also significantly higher (p?<?0.05) for fasiglifam 25?mg (30.2%) and 50?mg (54.8%) compared with placebo (13.8%). Fasiglifam significantly reduced fasting plasma glucose levels at all assessment points, starting from week 2. The incidence and types of treatment-emergent adverse events in each fasiglifam group were similar to those in the placebo group, and hypoglycaemia was reported in 1 patient receiving fasiglifam 50?mg. There were no clinically meaningful changes in body weight in any treatment group. CONCLUSIONS: Fasiglifam significantly improved glycaemic control and was well tolerated, with a low risk of hypoglycaemia in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise; however, in a recent review of data from overall fasiglifam global clinical trials, concerns about liver safety arose and the clinical development of fasiglifam was terminated after this trial was completed. Twit Text FOAVip Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial ????Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=25787200 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25787200 #FOAvip English Wikipedia <ref>{{Cite pmid|25787200 }}</ref> Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial #MMPMID25787200 Kaku K ; Enya K ; Nakaya R ; Ohira T ; Matsuno R Diabetes Obes Metab 2015[Jul]; 17 (7 ): 675-81 PMID25787200 show ga AIM: To assess the efficacy and safety of fasiglifam 25 and 50?mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. METHODS: This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasiglifam 25?mg (n?=?63) or 50?mg (n?=?62) or placebo (n?=?67) for 24?weeks. The primary efficacy endpoint was the change from baseline in glycated haemoglobin (HbA1c) at week 24. RESULTS: At week 24, both fasiglifam groups had significantly reduced HbA1c levels compared with the placebo group (p? |Aged [MESH] |Asian People [MESH] |Benzofurans/*therapeutic use [MESH] |Blood Glucose/analysis [MESH] |Diabetes Mellitus, Type 2/blood/*drug therapy [MESH] |Diet, Diabetic [MESH] |Double-Blind Method [MESH] |Exercise [MESH] |Female [MESH] |Glycated Hemoglobin/analysis [MESH] |Humans [MESH] |Hypoglycemia/chemically induced [MESH] |Hypoglycemic Agents/*therapeutic use [MESH] |Japan [MESH] |Male [MESH] |Middle Aged [MESH] |Receptors, G-Protein-Coupled/*agonists [MESH]Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled recep(epmc).pdf DeepDyve Pubget Overpricing